BAKER BROS ADVISORS LP
Q3 2024 Form 13-F
NEW YORK, NEW YORK
CIK 0001263508
· CRD 158149
· SEC-registered investment adviser
$9.6B Reported Value Total
BAKER BROTHERS INVESTMENTS reports 2 total accounts under management (AUM). There are 2 discretionary accounts valued at $18,024,640,582, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered
Discretionary Manager
Private funds (Form ADV)
7 funds
· $28.2B gross asset value
Hedge Fund: $28.2B
Source: Form ADV filed 2026-03-27
Reported value
$9.6B
Quarter over quarter
+21.9%
Holdings
92
Top-10 concentration
77.9%
Key People
Form ADV owners & control persons
Felix James Baker
MANAGING MEMBER
Julian Charles Baker
MANAGING MEMBER
Scott Lawrence Lessing
PRESIDENT, CHIEF COMPLIANCE OFFICER
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q3 2024 13F record
Q3 2024 13F filing summary
| Period of report | September 30, 2024 |
|---|---|
| Filed | November 14, 2024 |
| Form | 13F-HR |
| Reported value | $9.6B |
| Positions | 92 |
| Change in reported value | +23.3% |
| New positions | 6 |
| Exited positions | 8 |
| Position turnover | 14.0% |
| Top-10 concentration | 77.9% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
83 | $20.0B |
|
Q1 2026 13F
Filed May 15, 2026
|
84 | $17.4B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
85 | $17.1B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
89 | $13.8B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
88 | $10.3B |
|
Q1 2025 13F
Filed May 15, 2025
|
87 | $9.0B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
93 | $9.4B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
92 | $9.6B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
93 | $7.8B |
|
Q1 2024 13F
Filed May 15, 2024
|
87 | $8.0B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
82 | $8.8B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
99 | $17.4B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
106 | $17.3B |
|
Q1 2023 13F
Filed May 15, 2023
|
105 | $18.4B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
111 | $16.7B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
113 | $15.3B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
114 | $17.6B |
|
Q1 2022 13F
Filed May 16, 2022
|
115 | $17.4B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
116 | $20.6B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
116 | $22.8B |
33 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q3 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ONC BeiGene, Ltd. | $2.4B | 24.59% |
| 2 | INCY Incyte Corporation | $2.0B | 21.06% |
| 3 | ACAD ACADIA Pharmaceuticals Inc. | $659.5M | 6.83% |
| 4 | SMMT Summit Therapeutics Inc. | $534.9M | 5.54% |
| 5 | MDGL Madrigal Pharmaceuticals, Inc. | $419.0M | 4.34% |
| 6 | RVMD Revolution Medicines, Inc. | $343.3M | 3.56% |
| 7 | RYTM Rhythm Pharmaceuticals, Inc. | $335.2M | 3.47% |
| 8 | INSM Insmed Incorporated | $322.4M | 3.34% |
| 9 | KYMR Kymera Therapeutics, Inc. | $283.8M | 2.94% |
| 10 | BCYC Bicycle Therapeutics plc | $212.7M | 2.2% |
| 11 | EWTX Edgewise Therapeutics, Inc. | $155.9M | 1.62% |
| 12 | REPL Replimune Group, Inc. | $121.1M | 1.25% |
| 13 | ALKS Alkermes plc | $117.0M | 1.21% |
| 14 | DNLI Denali Therapeutics Inc. | $108.7M | 1.13% |
| 15 | INSM 0.75 06/01/28 Insmed Incorporated | $98.3M | 1.02% |
| 16 | RARE Ultragenyx Pharmaceutical Inc. | $87.6M | 0.91% |
| 17 | NRIX Nurix Therapeutics, Inc. | $87.2M | 0.9% |
| 18 | TRDA Entrada Therapeutics, Inc. | $77.8M | 0.81% |
| 19 | IMTX Immatics N.V. | $73.5M | 0.76% |
| 20 | ABCL AbCellera Biologics Inc. | $71.6M | 0.74% |
Values as reported on the Q3 2024 Form 13F. Every position is in the holdings table below.